Calroy Health Sciences has released randomized controlled trial (RCT) data showing its patented joint-health ingredient Cartigenix HP® delivered a 64% reduction in WOMAC pain scores and a 50% improvement in walking distance over a 90-day intervention period. The findings, disclosed this month, also include measurable shifts in cartilage regeneration biomarkers — a mechanistic signal that could meaningfully differentiate the ingredient in an increasingly crowded joint-support category.
The trial's primary clinical endpoint, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), is a validated, peer-reviewed instrument widely accepted for osteoarthritis research and regulatory submissions. A 64% reduction in WOMAC pain scores in a double-blind, placebo-controlled design represents a clinically meaningful outcome by most published thresholds. The additional 50% gain in functional walking distance addresses both pain and mobility — two distinct axes that operators and formulators frequently struggle to substantiate simultaneously in a single finished formulation. Calroy has not yet disclosed the full dosing schedule or the specific mg/serving of the standardized extract, data points that contract manufacturers and white-label partners will need before scaling commercial batches.
Cartigenix HP® enters a joint-health ingredients market that analysts have valued in the multi-billion-dollar range globally, with collagen peptides, glucosamine, chondroitin, and more recently UC-II® undenatured collagen commanding the largest shelf presence across sports nutrition and healthy-aging SKUs. The emergence of biomarker-substantiated claims — beyond symptomatic relief — reflects a broader trend toward mechanism-of-action storytelling that resonates with both specialty retail buyers and direct-to-consumer subscription platforms. Distribution details for Cartigenix HP® have not been announced, but the RCT data package positions the ingredient for premium-tier joint formulas targeting adults 45 and older, a demographic driving outsized growth in the functional food and dietary supplement channels. For formulators evaluating the ingredient, GRAS status and any existing New Dietary Ingredient (NDI) notification history will be critical due-diligence checkpoints before launch.
Operator interest in joint health has accelerated as consumers increasingly seek food-format delivery — functional beverages, gummies, and fortified snacks — alongside traditional softgels and capsules. Calroy's biomarker data could support structure-function claims around cartilage maintenance, provided the language is carefully scoped to comply with 21 CFR 101.93 notification requirements. Brands exploring co-manufacturing partnerships around Cartigenix HP® should request the full clinical dossier, including blinding procedures, dropout rates, and any subgroup analyses, before committing to label claims. Coverage of adjacent joint-health ingredient launches and the evolving regulatory landscape for musculoskeletal claims can be found in Supplement Regulation and Clinical Nutrition coverage at Functional News.
Calroy Health Sciences has not confirmed peer-reviewed publication status for the trial or announced a commercialization timeline for broad ingredient supply, leaving some open questions for brands seeking long-term supply-chain security. That said, the combination of a validated pain index, a functional performance metric, and cartilage biomarker data in a single 90-day RCT gives Cartigenix HP® one of the more complete evidence packages to emerge from the joint-health ingredient pipeline in recent quarters. This publication was produced in partnership with the Food & Beverage Magazine network.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.